Brief: PYC Therapeutics Says U.S. FDA Clears Co To Start Human Trial In Retinitis Pigmentosa Type 11
05/03/2023 22:42
March 6 (Reuters) - PYC Therapeutics Ltd PYC.AX :
* US FDA CLEARS PYC TO COMMENCE FIRST EVER HUMAN TRIAL IN
RETINITIS PIGMENTOSA TYPE 11
Source text for Eikon: ID:nASX2GwN7J
Further company coverage: PYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director